secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001437749-26-010409
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica reports FY2025 cash $59.9M; ReMEDy2 trial nearing 70% interim enrollment
--------------------------------------------------------------------------------

- Cash and investments $59.9M at Dec 31, 2025, up from $44.1M; runway through 2H 2027.
- ReMEDy2 Phase 2/3 AIS trial approaching 70% of required interim enrollment; analysis in 2H 2026.
- R&D expenses $24.6M vs $19.1M YoY driven by ReMEDy2 expansion and PE program costs.
- G&A expenses $9.8M vs $7.6M YoY; net cash used in ops $29.1M vs $22.1M.
- PE Phase 2 IST Part 1a enrollment ongoing; DiaMedica-sponsored Phase 2 to start later 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774926010409/0001437749-26-010409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774926010409/dmtp20260330_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-010409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer